Tumor vaccine based on RNA (Ribonucleic Acid), preparation method, immunologic adjuvant and application
Through the combined use of circRNA-based tumor vaccine and TLR4 agonist, the problems of limited effect of TLR agonist and low immunogenicity in hepatocellular carcinoma in the prior art have been solved, and tumor growth inhibition and immunotherapy effects have been improved, and it has relatively good results. Good security.
Patent Information
- Application Number
- CN202411128663.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-06-21
- Filing Date
- 2024-08-16
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-16
AI Technical Summary
The existing TLR agonists have limited immunotherapy effects in tumor treatment, and there are serious toxic side effects and adverse reactions when used alone. The low immunogenicity of hepatocellular carcinoma leads to the hindering of the antigen presentation process, making it difficult to induce an immune response of sufficient strength.
Using a tumor vaccine based on circular RNA (circRNA) encoding, combined with TLR4 agonist, improves the translation efficiency of antigen RNA by modifying ribosome entry site (IRES) and introduces circRNA into cells using lipid nanoparticle (LNP) vector. , combined with TLR4 agonist, reshape the tumor microenvironment and improve antigen presentation efficiency and immune response.
Significantly inhibit tumor growth, improve the effect of hepatocellular carcinoma immunotherapy, enhance the responsiveness of immunotherapy, reduce the risk of adverse reactions, and provide a safe and efficient tumor vaccine solution.
Smart Images

Figure CN119015401A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of antigen RNA in tumor treatment and drug preparation, and in particular to an RNA-based tumor vaccine, a preparation method, an immune adjuvant and application. Background Art
[0002] Tumor vaccines are a promising anti-tumor immunotherapy method. Among them, RNA vaccines are a new trend in the development of tumor vaccines in the future. It uses lipid nanoparticles (LNP) to introduce mRNA into the body to quickly express antigen proteins to stimulate the body to produce specific immune responses, achieve long-term tumor regression and prevent metastasis, and avoid the risk of genome integration or T cell tolerance. So far, researchers have developed a variety of mRNA tumor vaccines, some of which have entered the clinical trial stage in non-small cell lung cancer, melanoma and gastrointestinal tumors, and are gradually evaluating safety and efficacy. However, due to the limitations of mRNA such as easy degradation, large molecular weight, charge properties, and limited targeting, the clinical benefits of mRNA vaccines in tumor treatment are limited. Circular RNA (circRNA) causes a special ring structure, which makes it have higher stability and RNase resistance, which makes up for the shortcomings of linear mRNA vaccines and thus has broader application prospects. Previous studies have reported that circRNA vaccines against the new coronavirus have played a better immune protection role than mRNA, but no circRNA-based cancer vaccine has been successfully developed. Therefore, further research and development of novel circRNA tumor vaccines and their role in treating hepatocellular carcinoma will have important clinical significance and social benefits for improving the immunotherapy effect of liver cancer.
[0003] Toll-like receptors agonists are a class of drugs with great potential, which can efficiently activate antigen presenting cells to produce specific immune responses. However, the clinical treatment effects in the existing technologies are not very ideal. For example, small molecule drugs represented by imiquimod and resiquimod have been launched one after another, but the clinical efficacy is still not optimistic. PF-3512676 is a TLR9B agonist developed by Pfizer more than 10 years ago, but its development has been terminated due to negative results of the Phase III trial. Another TLR7 agonist (GS-9620) lacked significant antiviral activity in a Phase 1 / 2 study of clinical trials of hepatitis B virus infection, although no adverse reactions were observed. The newer generation of TLR8 agonists, although they show a strong affinity for pathogen-related molecular proteins, can induce liver monocytes and DC cells to produce abundant IL-12 and IL-18, so they will produce a violent IFN-γ response in the liver, inducing an inflammatory factor storm, leading to serious adverse reactions in the body. The above research results all indicate that TLR agonists alone are difficult to induce an effective immune response, and therapeutic doses generally have strong toxic side effects, resulting in severe systemic inflammatory side effects and even fatal drug side effects, limiting their large-scale clinical application.
[0004] In addition, the low immunogenicity of hepatocellular carcinoma and the obstruction of the antigen presentation process are important factors leading to resistance to immunotherapy. Due to the existence of antigen modulation, some tumor cells with strong immunogenicity are eliminated after inducing the body's anti-tumor immune response, and tumor cells with weaker immunogenicity continue to proliferate after escaping the body's immune surveillance, eventually causing the weakening of tumor cell immunogenicity. Due to the infiltration of suppressive immune cells in the liver cancer microenvironment, the activity of antigen-presenting cells such as DC and natural killer cells (NK) is weakened, making it impossible for new antigens to be effectively presented and difficult to induce an immune response of sufficient strength.
[0005] Through the above analysis, the problems and defects of the existing technology are as follows: On the one hand, the existing clinical trial data suggest that the immunotherapy effect of TLRs agonists in tumor patients is limited, and the clinical benefits of advanced patients are poor. Moreover, the use of TLR agonists alone can activate the immune system in a non-specific manner, leading to dose-limiting toxicity and potential adverse reactions such as fever, flu-like symptoms and inflammation, making it difficult to predict and control immune responses. On the other hand, the low immunogenicity of hepatocellular carcinoma and the obstruction of the antigen presentation process are important factors leading to resistance to immunotherapy.
[0006] Therefore, there is a need to provide a tumor vaccine that can both promote the presentation efficiency of antigen cells and effectively control the toxic side effects of agonists. Summary of the invention
[0007] The technical problem to be solved by the present invention is to provide an RNA-based tumor vaccine, preparation method, immune adjuvant, carrier and application in view of the problems existing in the background technology.
[0008] In order to solve the above technical problems, the present invention adopts the following technical solutions:
[0009] In a first aspect, the present invention provides an RNA-based tumor vaccine, which can specifically act on tumors that positively express GPC3, such as hepatocellular carcinoma, ovarian clear cell carcinoma, yolk sac carcinoma, etc. The tumor vaccine includes circular RNA that can encode an immunogenic polypeptide.
[0010] Preferably, the circular RNA is configured to specifically encode the immunogenic polypeptide GPC3.
[0011] Preferably, the tumor vaccine introduces a ribosome entry site IRES modification into the circular RNA encoding the immunogenic polypeptide GPC3 (i.e., circ-GPC3), such as Figure 2 As shown, the translation efficiency of tumor-specific antigen RNA can be increased by artificially introducing ribosome entry site (IRES) modification.
[0012] The circular RNA encoding the immunogenic polypeptide is preferably circ-GPC3. In the present invention, the GPC3 encoded by the circular RNA, i.e., circ-GPC3, has a covalently closed ring structure, such as Figure 2 As shown, it can protect it from exonuclease-mediated degradation, has a longer half-life and higher stability than mRNA, and can ensure the continuous expression of immunogenic proteins. In addition, the circRNA in the present invention can enhance the immunogenicity of tumor cells by interacting with immune cells and cytokines in the tumor microenvironment, thereby improving the responsiveness to immunotherapy.
[0013] The gene sequence of circ-GPC3 is shown in SEQ NO: 1 in the sequence table.
[0014] SEQ NO:1
[0015]
[0016] The amino acid sequence of the polypeptide encoded by the circ-GPC3 is shown in SEQ NO: 2 in the sequence list.
[0017] SEQ NO:2
[0018] MAGTVRTACLLVAMLLGLGCLGQAQPPPPPDATCHVRSFFQRLQPGLKWVPETPVPGSDLQVCLPKGPTCCSRKMEEKYQLTARLNMEQLLQSASMELKFLIIQNAAVFQEAFEIVVRHAKNYTNAMFKNNYPSLTPQAFEFV GEFFTDVSLYILGSDINVDDMVNELFDSLFPVIYTQMMNPGLPESVLDINECLRGARRDLKVFGSFPKLIMTQVSKSLQVTRIFLQALNLGIEVINTTDHLKFSKDCGRMLTRMWYCSYCQGLMMVKPCGGYCNVVMQGCMAGVV EIDKYWREYILSLEELVNGMYRIYDMENVLLGLFSTIHDSIQYVQKNGGKLTTTIGKLCAHSQQRQYRSAYYPEDLFIDKKILKVAHVEHEETLSSRRRELIQKLKSFINFYSALPGYICSHSPVAENDTLCWNGQELVERYSQK AARNGMKNQFNLHELKMKGPEPVVSQIIDKLKHINQLLRTMSVPKGKVLDKSLDEEGLESGDCGDDEDECIGSSSGDGMVKVKNQLRFLAELAYDLDVDDAPGNKQHGNQKDNEITTSHSVGNMPSPLKILISVAIYVACFFFLVH
[0019] Preferably, the tumor vaccine of the present invention further comprises a combined immune adjuvant, wherein the combined immune adjuvant is a Toll-like receptor agonist, and more preferably a Toll-like receptor agonist-4 (TLR agonist-4).
[0020] In a second aspect of the present invention, the present invention provides a use of a Toll-like receptor agonist in the preparation of an RNA-based tumor vaccine.
[0021] In a third aspect of the present invention, the present invention provides a method for preparing an RNA-based tumor vaccine, wherein the method is configured to prepare the tumor vaccine according to the first aspect of the present invention, and comprises the following specific steps:
[0022] (1) SM102, DMG-PEG2000, distearoyl phosphatidylcholine, and high-purity cholesterol CHO-HP were dissolved in anhydrous ethanol and prepared into an organic phase containing lipid molecules according to a certain molar percentage as shown in Table 1;
[0023] Table 1
[0024] Components Mole Percent SM102 30-50% DMG-PEG2000 1.5-2.5% DSPC 10-20% cholesterol 38.5-47.5%
[0025] (2) diluting the purified mRNA / circRNA with a citric acid-sodium citrate buffer at pH 4.5-5.5 to obtain an aqueous phase containing mRNA / circRNA nucleic acid molecules;
[0026] (3) using microfluidic technology to fully mix the organic phase prepared in step (1) and the aqueous phase prepared in step (2);
[0027] (4) The organic solvent was removed by ultrafiltration and placed in a shaker at 2-10°C overnight to obtain lipid nanoparticles loaded with mRNA / circRNA;
[0028] (5) Combined immune adjuvants are prepared in proportion. In a fourth aspect of the present invention, based on the above technical solution, the present invention provides an application of a tumor vaccine, immune adjuvant and / or carrier of antigen RNA in immunotherapy of hepatocellular carcinoma.
[0029] In a fifth aspect of the present invention, based on the above technical solutions, the present invention provides an application of a tumor vaccine, an immune adjuvant and / or a carrier of an antigen RNA in the preparation of an immune drug for hepatocellular carcinoma.
[0030] The beneficial effects of the present invention are:
[0031] 1. The circular RNA in the present invention encodes a polypeptide with tumor immunotherapy activity. The coding sequence obtained by adding preferred modified nucleotides (IRES sequence) by RNA modification means further improves the efficiency of GPC3 protein translation while retaining its antigenic epitope. The present invention discovers for the first time that preparations containing circular RNA molecules can significantly inhibit tumor growth in tumor patients and exert significant tumor treatment effects in tumor mouse models, providing a new therapeutic drug with great application prospects for tumor immunotherapy.
[0032] 2. The present invention optimizes and designs the GPC3 encoding circRNA sequence, and carries the LNP drug delivery system to construct a new RNA vaccine combined with TLR4 agonist treatment, which is expected to reshape the tumor suppressive immune microenvironment, improve the efficiency of tumor antigen presentation, increase the anti-tumor immune effect, and provide a new strategy for the immunotherapy of hepatocellular carcinoma. The treatment scheme of tumor vaccine combined with adjuvant in the present invention can accelerate the presentation of liver cancer-related tumor antigens, upregulate the expression of co-stimulatory molecules on the surface of dendritic cells, and promote the secretion of cytokines such as TNF-a and IFN-r, drive the remodeling of the tumor microenvironment, thereby improving immunotherapy resistance, and its preparation method is simple and easy to repeat, easy to process and produce on a large scale, can enhance the immunotherapy effect of liver cancer, and has good application prospects.
[0033] 3. The TLR4 agonist selected as the immune adjuvant of the tumor vaccine in the present invention has the following advantages compared with other types of TLR agonists:
[0034] (1) Strong immune activation. TLR4 agonists can activate innate and adaptive immune responses, leading to the activation of antigen-presenting cells such as dendritic cells, and then stimulating T cell responses.
[0035] (2) Inducing Th1 response. TLR4 agonists can bias the immune response toward Th1 response, which is crucial for controlling intracellular infection and anti-tumor immunity.
[0036] (3) Low toxicity. TLR4 agonists have good safety. The results of in vivo and in vitro experiments indicate that the drug is safe to use and has few adverse reactions.
[0037] (4) Wide applicability. Other types of TLR agonists, such as TLR3 and TLR9 agonists, have considerable limitations as immune adjuvants. For example, TLR3 agonists are mainly expressed in endosomes, so their ability to activate immune cells outside these compartments is limited. TLR9 agonists are mainly expressed in B cells and plasmacytoid dendritic cells, which limits their ability to activate other immune cells such as T cells. However, the TLR4 selected in the present invention is expressed in a variety of immune cells, including dendritic cells, macrophages and B cells. The widespread expression of TLR4 enables TLR4 agonists to activate a variety of immune pathways, thereby generating powerful and diverse immune responses, showing promise in improving therapeutic efficacy and overcoming immune tolerance to cancer.
[0038] (5) Adjuvant synergy. TLR4 agonists can synergize with tumor antigens to further enhance immune activation and improve vaccine efficacy. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] Figure 1 It is a map of the in vitro transcription template plasmid mRNA-GPC3 in the present invention.
[0040] Figure 2 It is a map of the in vitro transcription template plasmid circRNA-GPC3 in the present invention.
[0041] Figure 3 This is a graph showing the results of detecting mRNA-GPC3 and circRNA-GPC3 encoded polypeptides in two liver cancer cell lines in Example 2.
[0042] Figure 4 This is a comparison photo of the fluorescence experiments of mRNA-GPC3-EGFP and circGPC3-EGFP in Example 3.
[0043] Figure 5 This is a comparison chart of the expression of linear and circular Luciferase RNA in mice in Example 4.
[0044] Figure 6 This is the tumor growth curve of mice in the liver cancer model treated with the circRNA vaccine encoding GPC3 combined with various TLR agonists in Example 6.
[0045] Figure 7 This is a quantitative analysis of the tumor mass of mice in the liver cancer model treated with the circRNA vaccine encoding GPC3 combined with various TLR agonists in Example 6.
[0046] Figure 8 This is a graph showing the tumor growth curve of mice in a liver cancer model treated with a circRNA vaccine encoding GPC3 combined with a TLR4 agonist in Example 6.
[0047] Fig. 9 This is a quantitative analysis of tumor mass in mice in a liver cancer model treated with a circRNA vaccine encoding GPC3 combined with a TLR4 agonist in Example 6.
[0048] Fig.10 This is a flow cytometry experiment scatter plot verifying the activation of anti-tumor immune response (CD8+T cells) by circRNA vaccine combined with TLR4 agonist treatment in Example 6.
[0049] Fig.11 This is a quantitative graph of the results of Example 6 verifying that the circRNA vaccine combined with TLR4 agonist therapy activates anti-tumor immune response (CD8+T cells).
[0050] Fig.12 This is a quantitative graph of the mouse serum ALT results in evaluating the biosafety of the treatment regimen in Example 7.
[0051] Fig.13 This is a quantitative graph of the mouse serum AST results in evaluating the biosafety of the treatment regimen in Example 7.
[0052] Fig.14 It is the HE pathological section picture of the main organs of mice used in the evaluation of the biosafety of the treatment regimen in Example 7. DETAILED DESCRIPTION
[0053] In order to make the purpose, technical solutions and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with the embodiments and the accompanying drawings. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention. Without departing from the spirit and essence of the present invention, the modification or replacement of the method, steps or conditions of the present invention all belong to the scope of the present invention.
[0054] Unless otherwise specified, the experimental methods used in the following examples are all conventional methods; the materials and reagents used are reagents and materials that can be obtained from commercial channels unless otherwise specified.
[0055] In the embodiments of the present invention, the prevention and treatment of hepatocellular carcinoma is taken as a specific application example, but the embodiments of the present invention are not limited thereto.
[0056] Example 1: Preparation of lipid nanoparticles loaded with antigen-encoding RNA.
[0057] This embodiment provides a method for preparing lipid nanoparticles containing RNA nucleic acid molecules in the tumor vaccine of the present invention.
[0058] First, SM102, DMG-PEG2000, distearoylphosphatidylcholine (DSPC), and high-purity cholesterol CHO-HP were dissolved in anhydrous ethanol and prepared into lipid ethanol solution according to the molar percentage shown in Table 2. Then, the purified mRNA / circRNA was diluted with citric acid-sodium citrate buffer (pH=4.5) for use. Further, using microfluidics technology (TYD01-01 (V3) type, Leadfluid), the organic phase containing lipid molecules (SM102, DMG-PEG2000, DSPC, cholesterol) and the aqueous phase containing nucleic acid molecules (mRNA / circRNA) (diluted with citric acid-sodium citrate buffer (pH=4.5)) were fully mixed, and the mixing ratio was 1:1-1:10 (preferably 1:3), and the organic solvent was further removed by ultrafiltration, and placed in a 4°C shaker overnight to obtain lipid nanoparticles loaded with mRNA / circRNA.
[0059] Table 2
[0060] Components Mole Percent SM102 50% DMG-PEG2000 1.5% DSPC 10% cholesterol 38.5%
[0061] Example 2: Verification of mRNA / circRNA encoding polypeptide GPC3 in liver cancer cells.
[0062] 1 × 10 cells were plated in a 6-well plate overnight. 5 The mRNA / circRNA-loaded lipid nanoparticles prepared by the method described in Example 1 were transfected into the cells. Total protein in the cells was extracted 48 hours after cell transfection. The protein encoded by the mRNA / circRNA was verified by Western Blot experiment. The results showed that circGPC3 has the function of encoding polypeptides, and the expression level of the encoded polypeptides in liver cancer cells is significantly higher than that of the polypeptides encoded by mRNA-GPC3. Figure 3 shown.
[0063] Example 3: Verification of mRNA / circRNA expression in liver cancer cells.
[0064] 1 × 10 cells were plated in a 6-well plate overnight. 5 A HuH-7 liver cancer cell line was used to transfect the cells with mRNA-GPC3-EGFP@LNP or circGPC3-EGFP@LNP encoding the green fluorescent protein EGFP prepared by the above method. After 24 hours of cell transfection, the cells were washed 3 times with PBS and Hoechst was added to stain the nucleus for 10 minutes. The green fluorescence was observed using a laser confocal microscope. The results showed that green fluorescence could be successfully expressed in tumor cells using mRNA@LNP or circRNA@LNP, and the expression effect of circRNA was better than that of mRNA. It is worth noting that after 96 hours, fluorescence could still be observed in the circRNA group, while the fluorescence of the mRNA group was very weak or even disappeared at this time. The verification of this example shows that circRNA is more stable and has a longer expression time than mRNA, indicating that the method in Example 1 can be used to express specific antigen proteins in tumor cells and is preferably circRNA, such as Figure 4 shown.
[0065] Example 4: Expression of linear mRNA and circular circRNA in tumors.
[0066] For hepa1-6 tumor model mice, 10ug of nucleotide-modified linear mRNA and circular RNA encoding luciferase (fireflyluciferrase) were injected into the tail vein, and 6 hours later, D-luciferin potassium salt aqueous solution (15mg / ml) was injected into the mouse peritoneal cavity at a concentration of 10ul / g body weight. After 10-20 minutes of injection, the light signal reached the strongest stable plateau, and then in vivo fluorescence imaging was performed. The expression of linear and circular Luciferase RNA in vivo was analyzed by fluorescence intensity. Figure 5 shown. Figure 5 The left image shows the in vivo fluorescence imaging of mice injected with linear mRNA via tail vein; Figure 5 The right picture shows the in vivo fluorescence imaging of mice injected with circular RNA through the tail vein. Figure 5 It can be seen that at the same dose, circular RNA is more stable and expressed more significantly in the tumor than linear mRNA.
[0067] Example 6: Experiment on administration of circ-GPC3-encoded polypeptide combined with TLR4 agonism.
[0068] Healthy male C57BL / 6 mice aged 6-8 weeks were used to construct a mouse liver cancer model. Hepa1-6 mouse liver cancer cells were diluted to 2×10 7 cells / mL, 100 μl of cell suspension was slowly injected into the right hind armpit of the mouse to establish a mouse liver cancer subcutaneous tumor model. 3 At the same time, the tumor-bearing mice were randomly divided into 7 groups and treated as follows: ① blank control group; ② CircGPC3@LNP+TLR3 agonist group; ③ CircGPC3@LNP+TLR4 agonist group; ④ CircGPC3@LNP+TLR5 agonist group; ⑤ CircGPC3@LNP+TLR7 agonist group; ⑥ CircGPC3@LNP+TLR8 agonist group; ⑦ CircGPC3@LNP+TLR9 agonist group. TLR agonists were given by intraperitoneal injection, and CircGPC3@LNP vaccines were inoculated intratumorally at a dose of 10μg circRNA / mouse. The tumor growth of mice was observed and recorded every 2 days ( Figure 6 ). Calculation formula: tumor volume = (length × width × width) / 2. 15 days after immunization, mice were killed by cervical dislocation, and tumor tissues of mice in the above groups were collected and weighed ( Figure 7 ).Depend on Figure 5-6 It can be seen that CircGPC3@LNP combined with TLR agonist treatment can effectively inhibit tumor growth in mice. Among them, compared with other types of TLR agonists, after combined treatment with TLR4 agonist, the tumor growth rate of tumor-bearing mice was the slowest and the tumor burden was significantly reduced. Therefore, TLR4 agonist is preferred for combined treatment.
[0069] Furthermore, the same method was used to construct a mouse subcutaneous liver cancer tumor model and set up experimental groups: ① blank control group; ② TLR4 agonist group; ③ CircGPC3@LNP group; ④ CircGPC3@LNP+TLR4 agonist group. TLR4 agonist was given by intraperitoneal injection, and CircGPC3@LNP vaccine was inoculated intratumorally. The tumor growth of mice was observed and recorded every 2 days (see Appendix). Figure 815 days after immunization, the mice were killed by cervical dislocation, and the tumor tissues of the mice in the above groups were collected and weighed (see Appendix Fig. 9 After weighing, the tumor tissue was made into slices or single cell suspensions and T cell infiltration was observed (see Appendix Figure 10-11 ).
[0070] Example 7: Safety evaluation.
[0071] Fresh tissues were taken from the main organs of mice after treatment in the control group and each treatment group, and after being fixed with paraformaldehyde for 24-72h, 75% ethanol was dehydrated and made transparent. Then the transparent tissue block was embedded in molten paraffin to form a wax block. Further, the wax block was fixed on a slicer and cut into thin slices of 5-8 microns thick, and then the slices were flattened in warm water, and then attached to a glass slide, and the glass slide was placed in an oven for baking, so that the tissue slices were attached to the glass slide, and after further dewaxing and washing, hematoxylin-eosin (Hematoxylin-Eosin) staining was used, and the stained slices were dehydrated with pure alcohol, and then dimethyl-benzene was used to make the slices transparent. Neutral gum was dripped on the transparent slices, and coverslips were covered and sealed to obtain the HE pathological slices of the main organs of the mice, and the results were interpreted. In addition, blood was taken from the eye sockets of the mice, and serum was frozen for standby use by centrifugation for routine biochemical evaluation. The pathological conditions of each major organ and serum ALT / AST were analyzed by H&E staining to evaluate the biosafety of the solution in Example 6. The results showed that this method was safe and feasible. Figure 12-14 (shown)
[0072] The present invention is described exemplarily above in conjunction with the accompanying drawings, but the protection scope of the present invention is not limited thereto. As long as various improvements are made using the method concept and technical solution of the present invention, or the concept and technical solution of the present invention are directly applied to other occasions without improvement, they are all within the protection scope of the present invention.
Claims
1. An RNA-based tumor vaccine, It is characterized in that The tumor vaccine comprises circular RNA capable of encoding the immunogenic polypeptide GPC3.
2. An RNA-based tumor vaccine according to claim 1, It is characterized in that The circular RNA is configured to specifically encode the immunogenic polypeptide GPC3.
3. An RNA-based tumor vaccine according to claim 1 or 2, It is characterized in that The tumor vaccine introduces a ribosome entry site IRES modification into the RNA sequence encoding the immunogenic polypeptide GPC3.
4. An RNA-based tumor vaccine according to claim 2, It is characterized in that The gene sequence of GPC3 encoded by the circular RNA is shown in SEQ NO.1 in the sequence table.
5. The RNA-based tumor vaccine according to claim 1, It is characterized in that It also includes a combined immune adjuvant, wherein the combined immune adjuvant is a Toll-like receptor agonist.
6. A hepatocellular carcinoma-specific tumor vaccine based on RNA according to claim 5, It is characterized in that The content ratio of the circular RNA and the immune adjuvant is 0.75-1.25:0.75-1.
25.
7. Application of Toll-like receptor agonists as immune adjuvants in the preparation of RNA-based tumor vaccines.
8. A method for preparing an RNA-based tumor vaccine, It is characterized in that The preparation method is configured to prepare the tumor vaccine according to any one of claims 1 to 6, and the preparation method comprises the following specific steps: (1) dissolving SM102, DMG-PEG2000, distearoyl phosphatidylcholine, and high-purity cholesterol CHO-HP in anhydrous ethanol, and preparing an organic phase containing lipid molecules according to a certain molar percentage; (2) diluting the purified mRNA / circRNA with citric acid-sodium citrate buffer to obtain an aqueous phase containing mRNA / circRNA nucleic acid molecules; (3) using microfluidic technology to fully mix the organic phase prepared in step (1) and the aqueous phase prepared in step (2); (4) The organic solvent was removed by ultrafiltration and placed in a shaker at 2-10°C overnight to obtain lipid nanoparticles loaded with mRNA / circRNA; (5) Prepare combined immune adjuvants according to the proportion.
9. Application of an RNA-based tumor vaccine and immune adjuvant in tumor immunotherapy.
10. Application of an RNA-based tumor vaccine and immune adjuvant in the preparation of tumor immunotherapy drugs.
Citation Information
Patent Citations
Circular RNA compositions and methods
CA3172423A1
Circular RNA circ-GPC3 and detection reagent and application thereof
CN108384785A
Circular RNA vaccine and application thereof
CN113101363A
MRNA vaccine for treating lung cancer and bone metastasis thereof as well as preparation method and application of mRNA vaccine
CN115920019A
CAR-macrophage for blocking immunosuppression signal by targeting GPC3 as well as preparation method and application of CAR-macrophage
CN116555185A
Cited By
Anti-tumor vaccine and application thereof
CN119925299A
Targeting dendritic cell mRNA delivery system as well as preparation method and application thereof
CN120678948A
